摘要: The most advanced candidate vaccine against dengue viruses, called CYD-TDV, is progressing toward potential registration and review by the World Health Organization (WHO) in 2016. CYD-TDV a formulation of four chimeric yellow fever 17D each one engineered to express surface envelope prM (membrane) proteins from serotypes virus. protein target virus-neutralizing antibodies. safety efficacy after administration three doses over 12-month period was recently measured two pediatric phase 3 trials Latin America1 Southeast Asia.2 . . .